rs1131691159
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000051.4(ATM):c.5177+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000051.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.5177+1G>A | splice_donor_variant, intron_variant | Intron 34 of 62 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.00000137 AC: 2AN: 1460598Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726676
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:2
Variant summary: The ATM c.5177+1G>A variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict loss of canonical splicing donor site. These predictions was confirmed by functional studies showing variant led to exon skipping (Soukupova_2008). This variant is absent in 125804 control chromosomes. It has been reported in AT patient as well as BrC patient. Taken together, this variant is classified as pathogenic. -
This sequence change affects a donor splice site in intron 34 of the ATM gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with ataxia telangiectasia and/or breast cancer (PMID: 18497957, 26896183). ClinVar contains an entry for this variant (Variation ID: 429076). Studies have shown that disruption of this splice site results in exon 36 skipping, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 18497957). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.5177+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 33 of the ATM gene. This mutation has been reported in a patient diagnosed with bilateral breast cancer at ages 42y and 44y with a family history of pancreatic and breast cancers. In the same study, functional studies showed that this mutation results in skipping of coding exon 33 and that the aberrant transcript represented approximately 50% of the transcribed ATM mRNA (Soukupova J et al. Oncol Rep. 2008 Jun;19(6):1505-10). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at